Background: Dysregulation of miRNAs is associated with breast cancer. Results: MiR-9 overexpression and transcriptome analysis reveals novel miR-9 targets, including MTHFD2, which can recapitulate anti-proliferative effects of miR-9 overexpression. Conclusion: MiR-9 displays tumor-suppressor like activity in breast cancer cells, MTHFD2 contributes to this activity. Significance: Understanding miR-9 directed regulation of the breast cancer transcriptome is important for diagnosis and therapeutics.
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression posttranscriptionally. They mediate fundamental cellular processes such as differentiation, proliferation and apoptosis and are actively involved in carcinogenesis (1, 2) . Dysregulation of miRNAs can contribute to tumorigenesis (3) and miRNA expression patterns can classify tumor subtypes (4) . Several miRNAs have been experimentally validated to function as oncomirs (5) (6) (7) or tumor suppressor miRNAs (8, 9) . MiR-9, initially shown to function in neurogenesis (10) , is recently implicated in cancer. Although most evidence indicates tumor suppressor activity for miR-9 in cancer cells (11, 12) , conflicting findings exist (13) . Currently it is difficult to classify miR-9 as a tumor suppressor miRNA or an oncomir. For example, miR-9 is overexpressed in brain tumors (14) , induced by MYC in breast cancer cells enhancing metastasis (13, 15) , and knock-down of miR-9 decreased invasion of hepatocellular carcinoma cells (16) , all of which is indicative of an oncogenic potential. Conversely, in gastric cancer tissues miR-9 was shown to be downregulated (17) . Decreased expression of miR-9 has been also reported in gastric adenocarcinoma (18) , ovarian cancer (11, 19) and in malignant mesothelioma (20, 21) . Moreover, epigenetic inactivation of the miR-9 gene has been shown in breast cancer (22) (23) (24) , colorectal cancer (22) , renal cell carcinoma (25) and several other cancer cell lines and tumor tissues (12) , all of which is indicative of a tumor suppressor potential. To date, few miR-9 targets of relevance to cancer have been experimentally validated (26, 27) ; CBX7 in human glioma (28) , CDX2 in gastric cancer (29) , NFKB1 in ovarian cancer (19) and in gastric adenocarcinoma (18) and E-Cadherin when induced by MYC (15) . It remains unclear how miR-9 contributes to cancer cell growth or how cancer transcriptomes respond to loss/gain of miR-9 expression. This study investigates the effects of miR-9 over-expression on cancer cell growth and apoptosis, and further identifies global changes and novel direct targets in the transcriptome of the MCF-7 breast cancer cell line using a microarray profiling approach. We demonstrate that several cancer-associated genes are responsive to miR-9 overexpression and that miR-9 directly targets AP3B1, CCNG1, LARP1, MTHFD1L, MTHFD2
and SRPK1 post-transcriptionally. We also demonstrate that targeting MTHFD2 can be partially responsible for the anti-proliferative activity of miR-9 in breast cancer cells.
EXPERIMENTAL PROCEDURES
Patient samples and cell lines-Primary tumor (n=16) and normal breast (n=14) samples were obtained from patients at NUI Galway University hospital (Suppl. Table 3 ). Human breast adenocarcinoma cell lines MCF-7, MDA-MB-231 were cultured as previously described (30) and normal breast epithelial cell line MCF-10-2A was cultured based on ATCC recommendations. Constructs and transfections-For the microarray experiments, synthetic oligonucleotides (pre-9 and pre-ctr) (ABI, UK) were transfected at two dosages: 12.5 nM (1X) and 25 nM (2X) final concentrations. For all other experiments, a final concentration of 50 nM was used. SiRNAs for AP3B1, MTHFD1L, MTHFD2 and siControl (Qiagen, USA) were used in final 5 nM concentrations. The MTHFD2 ORF construct pCMV-MTHFD2-UTR (with full length 3'UTR) (Origene, USA) was used as wild type construct and pCMV-AC (Origene, USA) vector was used as empty vector (EV) control. A construct with mutated miR-9 binding sites on 3'UTR was generated (QuikChange Lightning Kit, Agilent Technologies, UK) designated as pCMV-MTHFD2-UTRmut. One µg of each plasmid (as well as pCMV empty vector (EV) control) and pre-9 (or pre-ctr) oligonucleotide were cotransfected into MCF-7, MDA-MB-231 and MCF-10-2A cells in 6-well plates using Lipofectamine 2000 reagent according to manufacturer's protocol (Invitrogen, USA). Quantitative RT-PCR-Total RNA and small RNAs were isolated using Nucleospin miRNA kit (Macherey-Nagel, Germany) and reversetranscribed using a RevertAid H-Minus First Strand cDNA Synthesis Kit (Fermentas, USA). Quantitative RT-PCR was performed using SYBR green assays (ABI, UK) and the reaction was run in a CFX96 system (Bio-Rad, USA). !-Actin and GAPDH were used as housekeeping controls. QRT-PCR analysis of miR-9 and RNU6B (housekeeping control) were conducted using Taqman miRNA assays (ABI, UK). Relative quantification of expression was calculated using MiR-9 inhibits proliferation of breast cancer cells 3 the 2 !""CT method in CFX96 system software. Ttest was used to determine statistical significance. Microarray Profiling and data analysis-RNA integrity number (RIN) was measured using Bioanalyzer (Agilent, UK) and good quality samples (RIN>8) were processed for hybridization into whole human genome Illumina bead arrays (Illumina, USA) in biological triplicates (Wellcome Trust Sanger Institute microarray core facility). All data was variance stabilizing transformed and robust spline normalized using the lumi package (Bioconductor). Differentially expressed genes were identified using LIMMA (p < 0.05, Signal Log Ratio (SLR) > 1.2). Putative microRNA targets were identified using MAMI microRNA target meta-predictor and TargetScan. MiR-9 seed region enrichment was identified using Sylamer. Enrichment analysis was performed using conditional hypergeometric tests. The microarray data is deposited at NCBI/GEO; accession number: GSE33952. Western blot and antibodies-Cells were washed with PBS and lysed in protein lysis buffer (0.1% TritonX-100, 0.1% SDS, 0.5% DOC in PBS). MTHFD1L protein (localized to mitochondria) was isolated using Mitochondria Isolation Kit (Thermo Scientific, USA) followed by lysis using RIPA buffer (31) . Proteins were quantified (Bradford Assay, Bio-Rad, USA) and 30 #g of each protein was separated on 10% SDS-PAGE and transferred to PVDF membrane. Blots were blocked in 5% milk-TBS-Tween-20. Following antibodies are used: primary antibodies (1:500-1000 dilution) anti-AP3B1 (#GTX113878S), anti-MTHFD2 (#GTX115482S) (GeneTex, USA), anti-MTHFD1L (32), anti-CCNG1 (#AP11209b) (Abgent, USA), anti-SRPK1 (#H00006732-A01) (Abnova, USA), anti-$-Actin (#A9169), secondary antibodies (1:10,000 dilution) anti-rabbit (#A9169), anti-mouse (#A0168) (Sigma, UK). Immunodetection was performed using enhanced chemiluminescence (ECL Plus Kit, Perkin Elmer) and visualized in G:Box Chemi imaging system (Syngene, UK). Cell viability and caspase-3/7 assays-For viability, cytotoxicity and caspase-3/7 analyses, cells were grown in 96-well plates and 48 hours post-transfection of overexpression constructs or oligonucleotides, ApoTox-Glo Triplex Assay was performed according to manufacturer's protocol (Promega, USA). This assay detects fluorogenic, cell-permanent peptide substrate (GF-AFC) for live-cell activity and cell-impermanent, fluorogenic peptide substrate (bis-AAF-R110) for dead-cell protease activity, resulting in ratiometric, inversely correlated measures of cell viability and cytotoxicity. Each well is normalized as live/dead cells making results comparable (well-to-well, plate-to-plate and day-to-day) since the ratio of viable cells to dead cells is independent of cell number. This followed addition of luminogenic DEVD-peptide substrate for caspase-3/7 and Ultra-Glo™ Recombinant Thermostable Luciferase onto cells. The luminescence output was measured with a luminometer. One µM of staurosporine (STS) treatment for three hours was used as positive control for apoptosis induction (33) to confirm the accuracy of the assay. Wound healing and invasion assays-Cells were grown to full confluence, transfected with pre-9 or pre-ctr and wounded by a sterile pipette tip. Images of the cells were taken under an inverted microscope at 0 hour, 24 hours and 48 hours time points after wounding. For invasion, following transfections, 2.5x10 4 MCF-7 or MDA-MB-231 cells (in serum starving medium; 0.1% FBS DMEM) were transferred into invasion chambers (BD Biosciences, Germany) fixed and stained according to manufacturer's protocol. The images of invaded and stained cells were taken from an inverted microscope and counted. Luciferase Reporter Assay-Full-length 3'UTR reporter constructs for AP3B1, CCNG1, MTHFD1L, MTHFD2, LARP1 and SRPK1 were obtained from Switchgear Genomics, USA. Constructs containing mutated miR-9 seed binding site were generated (QuikChange Lightning Kit, Agilent Technologies, UK). Each 3'UTR or mutated 3'UTR construct (100 ng) was cotransfected with pre-9 or pre-ctr synthetic oligonucleotides (50 nM) in 24-well plates. 48 hours post-transfection, LightSwitch luciferase assay solution (Switchgear Genomics, USA) was added onto cells, incubated for 30 min at room temperature and luminescence was read for 2 seconds in luminometer plate reader. Log2 ratios of targeting/non-targeting microRNA (pre-9/prectr) luciferase activity for each construct were plotted.
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RESULTS
Increasing miR-9 levels leads to decrease in cell viability and increase in apoptosis in MCF-7 cells-Quantitative analysis (Taqman qRT-PCR) of miR-9 expression levels in breast cancer cell lines MCF-7 and MDA-MB-231 and normal epithelial breast cell line MCF-10-2A indicated lower levels of miR-9 in cancer cell lines compared to MCF-10-2A ( Figure 1A) . The effect of miR-9 overexpression on tumor cell growth was investigated. MiR-9 expression levels could be increased up to 250 fold in the pre-9 synthetic oligonucleotide transfected MCF-7 cells compared to pre-ctr (scrambled control) transfected cells ( Figure 1B) . MiR-9 overexpressing cells lead to decreased viability and increased caspase-7 activity as an indicator of apoptosis ( Figure 1C) . Although staurosporine (STS) treatment did not cause a significant change in the viability of the MCF-7 cells, it was sufficient to increase caspase-7 activity as a positive control of apoptosis ( Figure 1C) . MCF-7 cells lack caspase-3 (34), and previous reports indicate that activation of caspase-7 occurs independent of caspase-3 in MCF-7 cells (35, 36) . Hence, similar to STS treatment effects observed, in the miR-9 overexpression (pre-9) caspase-7 activity was increased compared to control (pre-ctr) indicating caspase-3 independent caspase-7 activation in MCF-7 cells ( Figure 1C) . In addition to antiproliferation and pro-apoptotic effects, miR-9 overexpressing MCF-7 cells (pre-9) had slower motility (wound healing) compared to control (prectr) ( Figure 1D ). To further examine the phenotypic effects of miR-9 overexpression on breast cancer cells, the invasion of MCF-7 (noninvasive, ER+) and MDA-MB-231 (highly invasive, ER-) cells was tested following miR-9 overexpression. No cell invasion was observed in MCF-7 cells. However, miR-9 overexpression (pre-9) significantly decreased the invasiveness of the highly invasive cell line MDA-MB-231 compared to control (pre-ctr) treatments ( Figure  1E ).
Genome-wide effects of miR-9 overexpression on MCF-7 transcriptome-To determine the global effects of miR-9 overexpression on the transcriptome of MCF-7 breast cancer cells microarray profiling was performed. MiR-9 was delivered at two dosages, designated 1X and 2X.
Quantitative analysis of miR-9 prior to the microarray analysis showed that the overexpression of miR-9 by providing a 2X dosage of the microRNA (pre-9) did not increase intracellular levels by two fold. However, there was a significant increase in miR-9 levels up to 1.5 fold compared to the 1X microRNA dosage (data not shown). Differentially expressed genes were identified for the 1X and 2X treatments separately (compared to their corresponding controls). A total of 516 differentially expressed genes were identified in miR-9 overexpressing MCF-7 cells compared to controls (p < 0.05, SLR > log2 1.2). Among these, 145 differentially expressed genes were specific to 1X dosage and 121 genes were specific to 2X dosage treatments. Two hundred and fifty genes were commonly differentially expressed in 1X and 2X (124 upregulated and 126 downregulated). There was no relationship observed between fold changes and dosages in the common differentially expressed genes, with both dosages displaying approximately the same fold change differences (Suppl. Figure S1 ), possibly due to saturation of miR-9 overexpression levels. Furthermore, a direct comparison of 1X (pre-9) versus 2X (pre-9) was performed, which identified no differential expression, indicating no observable dosage effect.
Downregulated genes responsive to miR-9 overexpression are enriched with miR-9 seed region binding sequences-To identify enrichment of miR-9 seed region binding sites in the 3'UTRs of differentially expressed genes Sylamer (SylArray) (37,38) analysis was performed. Briefly, all genes on the microarray were first ranked based by t-statistic. Sylamer detected significantly over-and under-represented words in the 3'UTRs of the ranked list of genes. Results showed significant enrichment (p-value < 1x10 -15 ) for canonical miR-9 seeds (6-mer, 7-mer and 8-mer) in downregulated genes in both dosages, 7-mer enrichment is shown (Figure 2A) . Analysis of all the differentially expressed genes (union of 1X and 2X; 516 genes) in the MAMI microRNA meta-predictor (mami.med.harvard.edu) identified predicted miR-9 targets (41 downregulated and 6 upregulated) ( Figure 2B ). The specific effects of direct miR-9 targeting are highlighted by the enrichment of miR-9 seed region binding sites in the 3'UTRs of genes observed to be 5 downregulated, indicating that the posttranscriptional regulatory role of miR-9 likely involves the direct targeting of multiple genes. Twenty six differentially expressed genes (20 downregulated and six upregulated genes) were selected for further analysis based on genes classified for enriched cancer related GO terms (e.g. cell proliferation, apoptosis, cell death) (Suppl. Table 1 ) or those that are predicted targets and displayed the greatest extreme in differential expression (independent of the GO term, based on lowest p-values) including 13 predicted targets of miR-9 (12 downregulated, one upregulated) (Suppl. Table 2 ). The differential regulation of 26 genes (20 downregulated and six upregulated) including NFKB1 as a known miR-9 target (19) in response to miR-9 overexpression was confirmed by Sybr green qRT-PCR for pre-9 treated samples compared to pre-ctr (t-test; p < 0.05) ( Figure 2C ).
Identification of six novel targets of miR-9-In most instances, microRNAs negatively regulate gene expression (i.e. reduce levels of mRNAs/proteins) (39,40). From the validated (downregulated) predicted targets, AP3B1, CCNG1, LARP1, MTHFD1L, MTHFD2 and SRPK1 were tested for direct miR-9 targeting using a 3'UTR luciferase-based reporter system (where one luciferase construct would contain a wild type 3'UTR while the other construct contains a disruption of the seed region of the miR-9 binding site) ( Figure 3A) . CCNG1, MTHFD2, LARP1 and SRPK1 were selected on the basis of their previous implications in breast cancer (41-44), while AP3B1 and MTHFD1L were selected as potential biomarkers. All of these genes were predicted to have one miR-9 binding site except MTHFD2, which has two predicted miR-9 binding sites ( Figure 3A) . All the predicted sites are annotated as conserved except for the miR-9 binding site in SRPK1, which is poorly conserved (TargetScan Release 5.2 June 2011) ( Figure 3A) . For the luciferase reporter analysis, in addition to construction of 3'UTR constructs where wild type miR-9 binding occurs, site-directed mutations in the miR-9 seed region in full-length 3'UTRs were introduced (MUT UTR) to perturb miR-9 binding.
For all the six genes tested, the wild type 3'UTR (WT UTR) constructs displayed significant (p<0.001) downregulation in luciferase activity when co-transfected with pre-9 (normalized to prectr) ( Figure 3B ) in MCF-7 cells. In contrast, in the mutated 3'UTR constructs (MUT UTR) luciferase activity was restored significantly, confirming the functionality of miR-9 binding sites in the 3'UTR of these genes ( Figure 3B ). In addition, the effect of miR-9 binding was also tested at the protein level for all six genes, which indicated miR-9 overexpression induced reductions in protein levels for AP3B1, CCNG1, LARP1, MTHFD1L, MTHFD2 and SRPK1 ( Figure 3C ). Since MTHFD2 3'UTR contains two putative miR-9 binding sites and there is no detailed research reported on its activity in cancer cells, we focused on identification of the effects of MTHFD2 on three cell lines: MCF-7, MDA-MB-231 (breast cancer) and MCF-10-2A (normal breast) (see Suppl. Figure S2 for all the MCF-10-2A results). In addition to MCF-7 cells (Figure 3B ), luciferase assay for MTHFD2 3'UTR was also performed in MDA-MB-231 and MCF-10-2A cells. In MCF-10-2A cells, despite the decreased luciferase activity in wild type construct (WT), the mutated construct (MUT) displayed no significant restoration of luciferase activity (Suppl. Figure S2A ). However, a slight suppression at mRNA and protein levels of MTHFD2 was observed upon miR-9 overexpression in MCF-10-2A cells (Suppl. Figure S2B ). In contrast, in MDA-MB-231 cells, the wild type construct (WT UTR) displayed lower luciferase activity whereas mutated construct (MUT UTR) restored the luciferase activity significantly (Figure 3D ), suggesting that a miR-9:MTHFD2 regulatory interaction occurs in two different breast cancer cell lines. The suppressive effect of miR-9 on MTHFD2 in MDA-MB-231 cells was also confirmed at mRNA and protein levels ( Figure 3E) . Overall, these results indicate that AP3B1, CCNG1, LARP1, MTHFD1L, MTHFD2, and SRPK1 are direct targets of miR-9, negatively regulated by miR-9 at the mRNA and protein levels.
Depletion of the miR-9 target MTHFD2 recapitulates the anti-proliferative effect of miR-9 overexpression in MCF-7 cells-To test whether the anti-proliferative effect of miR-9 overexpression is due to downregulation of its identified targets; siRNA knock-downs were performed for three genes AP3B1, MTHFD1L and MTHFD2 followed by viability and caspase-3/7 activity analyses. Successful knock-down in MCF-6 7 cells was confirmed for AP3B1 and MTHFD1L by qRT-PCR (Suppl. Figure S3A) . The viability of siMTHFD1L-transfected MCF-7 cells was significantly decreased whereas the siAP3B1-transfected cells showed no significant change in viability compared to the siControl (Suppl. Figure  S3B) . Analysis of caspase-3/7 activity indicated no significant change in siAP3B1-and siMTHFD1L-transfected MCF-7 cells compared to siControl (Suppl. Figure S3B) . The knock-down of MTHFD2 (siMTHFD2) was performed in three cell lines: MCF-7, MDA-MB-231 and MCF-10-2A. In MCF-10-2A cells successful knock-down was confirmed at mRNA level (Suppl. Figure  S2C) . The viability displayed no significant change, however caspase-3/7 activation was significantly (p=0.01) increased in the siMTHFD2-transfected MCF-10-2A cells (Suppl. Figure S2D ). Successful knock-down of MTHFD2 in MCF-7 and MDA-MB-231 cells was confirmed at mRNA ( Figure 4A ) and protein levels ( Figure  4B ). In MCF-7 cells, the viability was decreased (p=0.03) and caspase-3/7 activation was increased (p=0.003) upon MTHFD2 knock-down (siMTHFD2) (Figure 4C ). There was no significant change in the viability or caspase-3/7 activation in MDA-MB-231 cells ( Figure 4C) . However, MDA-MB-231 cells displayed reduced invasiveness ( Figure 4C ) upon MTHFD2 knockdown suggesting that MTHFD2 contributes to promoting invasiveness. These results indicate that (while displaying variable effects in different cell lines) MTHFD2 knock-down (siMTHFD2) can recapitulate the anti-proliferative, anti-invasive and pro-apoptotic activity of mir-9 overexpression (pre-9) (Figure 1) .
Overexpression of MTHFD2 with mutated miR-9 binding sites displays proliferative activity-To test for opposite effects to those observed in MTHFD2 knock-down, and to identify the contribution of miR-9-directed regulation on the potential oncogenic activity of MTHFD2, overexpression constructs for MTHFD2 with wild type 3'UTR (pCMV-MTHFD2-UTR) or 3'UTR with mutated miR-9 binding sites (pCMV-MTHFD2-UTRmut) or empty vector control (pCMV) ( Figure 5A ) were transfected in MCF-7, MDA-MB-231 and MCF-10-2A cells. The overexpression of MTHFD2 (via both wild type 3'UTR and mutated 3'UTR) was detected at mRNA and/or protein levels in all the cells (Figure 5A-B) (Suppl. Figure S2E for MCF-10-2A). The MCF-10-2A cells ectopically overexpressing miR-9 (pre-9) and MTHFD2 with mutated miR-9 binding sites (UTRmut) displayed higher MTHFD2 expression that may indicate the escape of MTHFD2 from miR-9 directed suppression due to the mutated binding sites. However, the viability and caspase-3/7 activity displayed no significant change upon MTHFD2 overexpression (Suppl. Figure S2F) . In contrast, despite the similar ectopic expression profile of MTHFD2 in UTR or UTRmut transfected samples, both MCF-7 and MDA-MB-231 cells displayed significantly greater viability and reduced apoptosis when MTHFD2 was overexpressed with mutated miR-9 binding sites (UTRmut) ( Figure 5C ). These findings highlight the significant contribution of miR-9-directed regulation on reducing the proliferative, and antiapoptotic capacity of MTHFD2. Furthermore, compared to control (EV), the invasiveness of MDA-MB-231 cells was increased when MTHFD2 was overexpressed with wild type 3'UTR (UTR) ( Figure 5C ) and this effect was greater (i.e. more invasiveness) when MTHFD2 was overexpressed with ablated miR-9 binding sites (UTRmut) (Figure 5C ), indicating that miR-9-directed regulation can limit the pro-invasive potential of MTHFD2.
MiR-9 and MTHFD2 show inverse expression levels in primary breast cancer samples-To test whether miR-9 and MTHFD2 expression levels are inversely correlated in clinical cancer samples, expression levels of miR-9 and MTHFD2 in 30 samples (16 primary breast cancer samples; eight non-metastatic tumor and eight metastatic tumor and 14 normal breast samples) were analyzed. The relative fold changes of miR-9 and MTHFD2 in tumor samples were normalized against the mean expression of normal breast tissue samples which were set to one, and presented as relative fold changes (Log2 ± SE) ( Figure 6A ). In six out of eight non-metastatic samples, miR-9 and MTHFD2 showed an inverse expression profile whereas in metastatic samples the trend was less obvious; three out of eight samples showed an inverse expression profile. Furthermore, two publically available datasets, Richardson_breast_2 (n=47) (45) and Zhao_breast (n=64) (46), available through the Oncomine TM database (v4. 4 
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Compendia Bioscience, Ann Arbor, MI) (47), confirmed higher expression levels of MTHFD2 in breast tumor samples compared to normal breast tissue ( Figure 6B ). This is consistent with increased MTHFD2 expression levels in breast cancer that was recently reported in a proteomics study with 21T breast cancer cell lines (derived from a single patient with metastatic breast cancer) (42).
DISCUSSION
The role of miR-9 in cancer biology is not well understood. This study demonstrates that endogenous miR-9 levels are lower in breast cancer cells compared to normal cells. It also provides evidence of direct miR-9 targets previously implicated in cancer. While miR-9 overexpression has been associated with colorectal cancer metastasis (48), its significant downregulation in gastric and clear cell renal carcinomas (17, 25) has also been reported. These conflicting findings on miR-9 expression (downregulation or overexpression in cancer cells) may be due to differential mature miR-9 processing from three different primary precursors where downregulation of miR-9 due to aberrant hypermethylation of any of the miR-9-1, miR-9-2 and miR-9-3 precursor regions have been reported in independent studies in different cancer types (25, 49, 50) . Our findings that endogenous miR-9 levels are lower in breast cancer cells compared to normal cells (for both cell lines and primary tumor samples), is similar to previous reports of lower levels of miR-9 associated with ovarian cancer, gastric carcinoma and clear cell renal carcinomas (17, 25, 51 ).
Changes in cell proliferation and apoptosis are key phenotypes observed in malignant transformation (52). Our results demonstrate that miR-9 overexpression decreases cell viability and increases apoptosis in MCF-7 breast cancer cells. As a caspase-3 null cell line (53), previous studies have shown that DEVDase activity can be increased in MCF-7 cells independent of caspase-3 whereby caspase-7 cleaves DEVD substituting caspase-3 (54-57). In this study, caspase-7 activity was increased indicating pro-apoptotic activity of miR-9 in MCF-7 cells. The anti-proliferative and pro-apoptotic effects of miR-9 are supportive of a tumor-suppressor-like role of miR-9 in the context of breast cancer cell proliferation, migration and apoptosis.
Invasiveness is one of the hallmarks of cancer (58) . Overexpression of some miRNAs (e.g. miR-21) has been shown to increase the invasiveness of normal and cancer cells (59, 60) . In some instances, non-invasive cell lines can be transformed into invasive cells, while in other cases the invasiveness of a cell line can be increased due to changes in the expression levels of specific miRNAs (or genes) (61, 62) . While our study demonstrates no effect of miR-9 overexpression on the invasiveness of the non-invasive MCF-7 cell line, the overexpression of miR-9 elicited a significant reduction in the invasiveness of the highly invasive MDA-MB-231 cell line. The lack of invasion observed in MCF-7 cells could be due to the poorly invasive nature of MCF-7 cells (63) . The reduction of invasion observed in the MDA-MB-231 cell line could be due to miR-9 directed downregulation or inactivation of pro-invasive genes, and indicates that miR-9 levels can affect invasiveness. Although miR-9 has been implicated in cancer biology in several studies, no genomewide transcriptome analysis of miR-9 expression effects in cancer cells has been reported to date. This study demonstrates that miR-9 overexpression in breast cancer cells in two dosages (1X and 2X) identifies 250 genes whose expression levels are responsive to miR-9, including 47 predicted miR-9 targets. The cancer relevance of miR-9 induced effects on the MCF-7 transcriptome is highlighted by cancer related GO terms (e.g. cell proliferation, apoptosis) being enriched in the genes differentially regulated.
The identification of predicted miR-9 target genes displaying reduced expression levels in MCF-7 cells when miR-9 is overexpressed suggests such genes are potential direct targets of miR-9. This study identifies and validates six genes as novel direct miR-9 targets, including five targets with previously identified roles in cancer (AP3B1, CCNG1, LARP1, MTHFD2 and SRPK1) and one target that not previously implicated in cancer (MTHFD1L) in MCF-7 cells. MTHFD2 was tested also in MDA-MB-231 and MCF-10-2A cells and confirmed as a direct target of miR-9 in MDA-MB-231 cells in addition to MCF-7. Interestingly, in MCF-10-2A cells luciferase activity remained 8 suppressed in the construct with mutated miR-9 binding sites, indicating no significant miR-9 contribution on MTHFD2 suppression in these cells, which may be a result of different cellular context in combination with other regulatory relationships.
For CCNG1, LARP1 and SRPK1, a functional role in cancer has been previously reported by knockdown experiments. CCNG1 (Cyclin-G1), a p53 target, has been implicated in cancer (64) (65) (66) (67) (68) and silencing of CCNG1 displayed decreased cell growth rate and invasion in hepatocarcinoma cells (65) . LARP1 (La ribonucleoprotein domain family, member 1), functions in vesicle transport. Silencing of LARP1 increased apoptosis in HeLa cells (69) . SRPK1 (SRSF protein kinase 1) functions in alternative splicing and has been implicated in many cancer types (70) (71) (72) (73) (74) . Silencing of SRPK1 increased apoptotic potential in breast and colonic tumor cell lines (70) , and decreased proliferative capacity in leukemic cells (75) . The observed reduction in mRNA and protein levels highlights that due to direct targeting by miR-9, the reduced activity of these oncogenic targets can potentially lead to suppression of tumorigenesis.
In addition, our study also provides the first knock-down experiments for three additional direct targets of miR-9, namely AP3B1, MTHFD1L and MTHFD2. We considered that the lack of experimental evidence of loss-of-function effects of these genes on cancer cells made them good candidates to investigate their possible involvement in breast carcinogenesis using a siRNA approach. AP3B1 (AP-3 complex subunit beta-1), involved in organelle biogenesis, has been investigated in relation to cancer in only a few studies (76, 77) . MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like) has been previously implicated in neural tube defects (78) . MTHFD2 (methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2), a mitochondrial bifunctional enzyme, is known to involve in folate metabolism (79) and loss-or gain-of function studies have not been described yet. A possible link between MTHFD2 and cancer; such as a SNP in MTHFD2 associated with increased risk of bladder cancer (80) , and a correlation of MTHFD2 expression with artesunate resistance in tumor cell lines (81) have been reported.
The individual effects of knock-down of MTHFD1L and AP3B1 showed only a small 15% decrease in viability in MCF-7 cells. In contrast, the knock-down of MTHFD2 significantly decreased cell viability and increased apoptosis in both MCF-7 and MDA-MB-231 cells, mimicking the phenotypic effect of miR-9 overexpression. Apart from the significant increase in caspase-3/7 activation in MCF-10-2A cells, no significant effect was observed in viability of MCF-10-2A cells or viability and caspase-3/7 activity of MDA-MB-231 cells following MTHFD2 knock-down. Similar findings indicating that overexpression or knock-down of a gene may not have an impact on cell proliferation but affect cancer cell invasion have been described (82, 83) . While the extent of the effect of MTHFD2 knock-down may not completely account for the overall extent of the phenotypic effects of miR-9, it is clear that knockdown of MTHFD2 can contribute to the phenotypic effects as seen for miR-9 overexpression in MCF-7 cells.
The overexpression of MTHFD2 with the wild type (UTR) or mutated (UTRmut) miR-9 binding sites displayed similar expression levels. MTHFD2 overexpression with mutated miR-9 binding sites (UTRmut) could be expected to display higher MTHFD2 levels due to "escaping" from miR-9 directed suppression. In the UTR transfected cells ectopically expressed miR-9 can target both endogenous and ectopically introduced MTHFD2, whereas in UTRmut transfected cells miR-9 can only target endogenous MTHFD2. We consider that due to high endogenous levels of MTHFD2, ectopically expressed miR-9 can still be captured by the endogenous MTHFD2 resulting in overall similar MTHFD2 expression compared to UTRmut. Potentially, much greater miR-9 ectopic expression in UTR-transfected cells should be sufficient for suppression of both endogenous and ectopically expressed MTHFD2, resulting in less MTHFD2 expression compared to UTRmuttransfected cells. MTHFD2 overexpression with wild type 3'UTR (UTR) had no effect on viability or apoptosis compared to empty vector control (EV). In contrast, MTHFD2 lacking miR-9 binding sites (UTRmut) displayed increased viability and 9 decreased apoptosis. This effect may indicate that the escape of MTHFD2 from miR-9 directed suppression potentiates its anti-proliferative activity. Indeed, the increased invasiveness observed for MDA-MB-231 cells during wild type MTHFD2 3'UTR (UTR) overexpression and the highest invasiveness observed with MTHFD2 mutated 3'UTR (UTRmut) highlight a contribution of miR-9 in balancing MTHFD2 levels (via suppression) to reduce invasiveness. Overall, the results suggest that, despite the variable effects of MTHFD2 on cell viability, apoptosis and invasion, the decreased MTHFD2 levels may be partially responsible for the effects observed during miR-9 overexpression in MCF-7 cells. In addition, MTHFD2 escape of the miR-9-directed suppression (3'UTR with no miR-9 binding sites) leads to a trend towards proliferative, antiapoptotic and pro-invasive activity, indicating that miR-9-directed MTHFD2 regulation is a contributor to anti-proliferative activity of miR-9.
The results in our study suggest a tumor suppressor-like activity of miR-9 when ectopically expressed in breast cancer cells. Moreover, transcriptome profiling of miR-9 overexpression identifies six novel direct targets of miR-9, including MTHFD2 (which when subject to knock-down recapitulated the anti-proliferative and pro-apoptotic activity of miR-9 overexpression in MCF-7 breast cancer cells). Furthermore, overexpression of MTHFD2 escaping miR-9 regulation suggests that miR-9 contributes to suppression of the potential oncogenic activity of MTHFD2. Taken together, our study highlights underexpression of miR-9 and overexpression of MTHFD2 in breast tumor tissues as potential expression level biomarkers. The expression levels of MTHFD2 can be controlled (downregulated) via increasing miR-9 expression in cancer cells, thereby reducing cell viability and enhancing apoptosis. In addition to the individual and negatively correlated expression profiles of miR-9 and MTHFD2, the interaction between miR-9 and MTHFD2 is significant in breast cancer cells and will next be subjected to further screening in population-size sample groups and possibly in combination with other miRNAs, which display promise as targets for breast cancer diagnosis and therapeutics. 
